Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL988827 | 0.86 | SLC6A4 (0.46) | SLC6A4CYP2A6KDM4ESLC6A2KCNH2 | |
| SCHEMBL17913433 | 0.83 | CYP1A2 (0.43) | SLC6A4CYP2A6KDM4ESLC6A2KCNH2 | |
| SCHEMBL2990425 | 0.80 | SLC6A4 (0.43) | SLC6A4KDM4ESLC6A2SLC6A3HPGD | |
| SCHEMBL30861233 | 0.80 | IDO1 (0.56) | HSD17B10HTR2ACA1CA2CA9 | |
| SCHEMBL11825653 | 0.80 | IDO1 (0.56) | HSD17B10HTR2ACA1CA2CA9 | |
| SCHEMBL5479089 | 0.80 | ACHE (0.50) | KDM4EHPGDMEN1KMT2ATSHR | |
| SCHEMBL11578002 | 0.79 | SLC6A4 (0.62) | SLC6A4CYP2A6KDM4ESLC6A2KCNH2 | |
| SCHEMBL4722473 | 0.79 | PTGER1 (0.48) | CYP2A6ALDH1A1 | |
| SCHEMBL12370675 | 0.79 | IDO1 (0.50) | SLC6A4KDM4ESLC6A2KCNH2SLC6A3 | |
| SCHEMBL4522555 | 0.79 | KDM4E (0.56) | KDM4ETSHRHTR2ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10179781-B2 | Sodium channel modulators for the treatment of pain | CHROMOCELL CORPORATION | 2019-01-15 | — | — | US | disclosed |
| US-10179781-B2 | Sodium channel modulators for the treatment of pain | CHROMOCELL CORPORATION | 2019-01-15 | — | — | US | disclosed |
| EP-3043787-B1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | CHROMOCELL CORP (US) | 2018-09-05 | — | — | EP | disclosed |
| EP-2968234-B1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORP (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-2968234-B1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORP (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20170304306-A1 | SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | CHROMOCELL CORPORATION (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170304306-A1 | SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | CHROMOCELL CORPORATION (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170304306-A1 | SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | CHROMOCELL CORPORATION (US) | 2017-10-26 | — | — | US | disclosed |
| EP-3193610-A1 | SELECTIVE NAV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | Chromocell Corporation (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9458118-B2 | Sodium channel modulators for the treatment of pain and diabetes | CHROMOCELL CORPORATION (US) | 2016-10-04 | — | — | US | disclosed |
| WO-2004009550-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1ALPHA BINDING TO ITS RECEPTOR CCR1 | PFIZER PRODUCTS INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| US-20030083335-A1 | Novel sulfonic acid derivatives | HAYWARD MATTHEW M (US) | 2003-05-01 | — | — | US | disclosed |
| WO-2003035627-A1 | PIPERAZINE DERIVATIVES WITH CCR1 RECEPTOR ANTAGONIST ACTIVITY | PFIZER PRODUCTS INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2002102787-A2 | NOVEL SULFONIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-12-27 | — | — | WO | disclosed |
| US-4460604-A | ANALGESICS, NARCOTIC ANTAGONIST | THE UPJOHN COMPANY (US) | 1984-07-17 | — | — | US | disclosed |
| US-4333759-A | Herbicidal 5-cyano-2,3-dihydro-benzofuran-2-ones | FISONS LIMITED (GB) | 1982-06-08 | — | — | US | disclosed |
| US-4263037-A | 5-Cyano-2,3-dihydrobenzofurans useful as herbicides | FISONS LIMITED (GB) | 1981-04-21 | — | — | US | disclosed |
| EP-0007719-A2 | Cyanbenzofuran derivatives, processes for their preparation and their use in herbicidal compositions; cyanobenzene, benzodioxepine, benzodioxaphosphepine and benzodioxathiepine derivatives | FBC LIMITED (GB) | 1980-02-06 | — | — | EP | disclosed |
| US-4180584-A | ANALGESIC; NARCOTIC ANTAGONIST | THE UPJOHN COMPANY (US) | 1979-12-25 | — | — | US | disclosed |
| US-4065573-A | ANALGESICS | THE UPJOHN COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179781-B2 | Sodium channel modulators for the treatment of pain | SCN7A, SCN10A, SCN2A | SLC6A4 227/4885CYP2A6 1856/4885KDM4E 3640/4885 |
| US-20030083335-A1 | Novel sulfonic acid derivatives | CCR1, MSR1, CXCR1 | SLC6A4 4137/4885CYP2A6 672/4885KDM4E 3866/4885 |
| US-20170304306-A1 | SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | SCN7A, SCN1A, SCN1B | SLC6A4 456/4885CYP2A6 2366/4885KDM4E 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.